Corvita in takeover talks:
This article was originally published in Clinica
Corvita, a developer of synthetic vascular grafts, is in discussions to be acquired by an unnamed company for around $10 a share. It is also holding discussions about a strategic alliance, the Florida-based company says. The statement came after the share price had risen to $10.63 by January 17th. In November 1994, Corvita floated at $5 a share.
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.